Mediastinal site

Source: Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: November 5, 2024 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Malignant Extragonadal Extracranial GCTs in Children / Standard Treatment Options for Malignant Extragonadal Extracranial GCTs in Prepubertal Children / Site-specific considerations for malignant extragonadal extracranial GCTs

Mediastinal GCTs account for 15% to 20% of malignant extragonadal extracranial GCTs in children.[5] The histology of mediastinal GCT is dependent on age, with teratomas predominating among infants and yolk sac tumors predominating among children aged 1 to 4 years.[7]

Source links and citations

Prepubertal children with mediastinal malignant teratomas are treated with tumor resection, which is curative in almost all patients.[7] Children with stage I to stage III nonmetastatic mediastinal GCTs who receive cisplatin-based chemotherapy have 5-year EFS and OS rates of 90%. However, patients with stage IV mediastinal tumors have EFS rates closer to 80%.[3,5,7]; [14][Level of evidence C1]

Source links and citations

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice